Strategy for the Prediction and Selection of Drug Substance Salt Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategy for the Prediction and Selection of Drug Substance Salt Forms
Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.


Pharmaceutical Technology


In Equation 2, the quantities in square brackets represent the molar concentrations of the various species, and the γ quantities are the activity coefficients of those species. For an acid capable of ionizing into a univalent anion, γH + and γA will be approximately equal, and γHA can be approximated as unity, so that the concentration-based equilibrium constant expression can be simply written as:



For weak acids, the magnitude of K A is very small, and therefore, the resulting H3O+ and A ions will be produced in small amounts. Under those conditions, both γH+ and γA will be approximately equal to one, facilitating the approximation that the thermodynamic equilibrium constant, K, equals the concentration-based ionization constant, K A . Making use of the Sørensen scale, one can define the pK A of a weak acid as:



A strong acid is defined as a substance that reacts completely with water so that the acid ionization constant defined in Equation 2 or 3 is very large. This situation can only be achieved if the conjugate base of the strong acid is very weak. A weak acid will be characterized by an acid ionization constant that is considerably less than unity, so that the position of equilibrium in the reaction represented in Equation 1 favors the existence of nonionized free acid. The implication of these properties is that the conjugate base of the weak acid must be moderately strong.

A discussion of the ionic equilibria associated with basic substances exactly parallels that just developed for acidic substances. A base is a substance capable of accepting a proton donated by another substance, such as water:



The basic substance (B) that originally accepted the proton becomes the conjugate acid (BH+ ) of that substance, since the conjugate acid could conceivably donate a proton to an even stronger base than the original substance. The concentration-based ionization constant expression corresponding to Equation 5 is:



and pK B is defined as:



A strong base is a substance that reacts completely with water, so the base ionization constant defined in Equation 6 is effectively infinite. This situation can only be realized if the conjugate acid of the strong base is very weak. Since the conjugate acid of a weak base will be moderately strong, the base ionization constant will be considerably less than one, and the position of equilibrium in the reaction represented in Equation 5 will favor the existence of a nonionized free base.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here